Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Megumi Kai"'
Autor:
Megumi Kai, Angela N. Marx, Diane D. Liu, Yu Shen, Hui Gao, James M. Reuben, Gary Whitman, Savitri Krishnamurthy, Merrick I. Ross, Jennifer K. Litton, Bora Lim, Nuhad Ibrahim, Takahiro Kogawa, Naoto T. Ueno
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurren
Externí odkaz:
https://doaj.org/article/c37b0ab005ba4205ac526ecb4d11aff8
Autor:
Evan N. Cohen, Gitanjali Jayachandran, Hui Gao, Phillip Peabody, Heather B. McBride, Franklin D. Alvarez, Megumi Kai, Juhee Song, Yu Shen, Jie S. Willey, Bora Lim, Vicente Valero, Naoto T. Ueno, James M. Reuben
Publikováno v:
Cancers, Vol 15, Iss 5, p 1616 (2023)
Circulating tumor cells (CTCs) are indicators of metastatic spread and progression. In a longitudinal, single-center trial of patients with metastatic breast cancer starting a new line of treatment, a microcavity array was used to enrich CTCs from 18
Externí odkaz:
https://doaj.org/article/22cbe30a996040929685f879f2eadd3f
Publikováno v:
Translational Oncology, Vol 12, Iss 9, Pp 1196-1205 (2019)
Insufficient delivery of systemically administered anticancer drugs to tumors can compromise therapeutic efficacy and develop drug delivery-based therapeutic resistance. Nanotherapeutics such as PEGylated liposomal doxorubicin (PLD) are designed to p
Externí odkaz:
https://doaj.org/article/6335f5a5acaf438f83ed4a629ed53b3e
Autor:
Yan Ting Liu, Shreya Goel, Megumi Kai, Jose Alberto Moran Guerrero, Thao Nguyen, Junhua Mai, Haifa Shen, Arturas Ziemys, Kenji Yokoi
Publikováno v:
Pharmaceutics, Vol 13, Iss 4, p 530 (2021)
We sought to determine if Stephen Paget’s “seed and soil” hypothesis of organ-preference patterns of cancer metastasis can explain the development of heterogeneity in a tumor microenvironment (TME) as well as immunotherapeutic delivery and effi
Externí odkaz:
https://doaj.org/article/e303172421e04154a9ed7e6c895b94e4
Autor:
Angela N. Marx, Megumi Kai, Min Fu, Hope E. Murphy, Jie S. Willey, Huiming Sun, Angela Alexander, Roland L. Bassett, Gary J. Whitman, H. T. Carisa Le-Petross, Miral Patel, Banu K. Arun, Sausan Abouharb, Parijatham S. Thomas, Carlos H. Barcenas, Nuhad K. Ibrahim, Vicente Valero, Naoto T. Ueno, Rachel M. Layman, Bora Lim, Wendy Woodward, Anthony Lucci
Publikováno v:
Cancer Research. 83:P4-06
Background: The pathologic complete response (pCR) rate in inflammatory breast cancer (IBC) patients is worse than in non-IBC patients; new drug combinations are warranted to improve pCR rates across all IBC molecular subtypes. Based on our preclinic
Publikováno v:
Expert opinion on therapeutic targets. 26(5)
Triple-negative breast cancer (TNBC) is the most fatal molecular subtype of breast cancer because of its aggressiveness and resistance to chemotherapy. FDA-approved therapies forIn this narrative review, we discuss emerging targets for TNBC treatment
Publikováno v:
Cancer Research. 81:PS18-42
Although immune-checkpoint inhibitors have improved the survival of patients with various types of metastatic tumor, intra- and inter-patient heterogeneities in the response of multiple tumors to the therapy have significantly limited clinical benefi
Autor:
Toshiaki Iwase, Angela Alexander, Vivian Chiv, Megumi Kai, Kumiko Kida, Charla Parker, Angela N. Marx, Evan Cohen, Hui Gao, James Reuben, Xiaoping Wang, Savitri Krishnamurthy, Diane Liu, Yu Shen, David Ramirez, Debu Tripathy, Daniel Booser, Clinton Yam, Vicente Valero, Bora Lim, Naoto T. Ueno, Jie S. Willey
Publikováno v:
Cancer Research. 83:P3-02
Accumulating physical and hematologic toxicities make the indefinite use of chemotherapy unfeasible for many patients with metastatic/recurrent HER2– IBC or TNBC. Whether maintenance immunotherapy has a role in the treatment of these patients is un
Autor:
Wendy A. Woodward, Diane Liu, Randa El-Zein, Naoto T. Ueno, Yu Shen, Bisrat G. Debeb, Kathy D. Miller, Wintana Balema, Beth Overmoyer, Huong T. Le-Petross, Megumi Kai
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 18, Pp 6261-6272 (2021)
Cancer Medicine, Vol 10, Iss 18, Pp 6261-6272 (2021)
Background Inflammatory breast cancer (IBC) is a clinical diagnosis. Here, we examined the association of a “classic” triad of clinical signs, swollen involved breast, nipple change, and diffuse skin change, with overall survival (OS). Method Bre
Autor:
Merrick I. Ross, Gary J. Whitman, Savitri Krishnamurthy, Hui Gao, James M. Reuben, Megumi Kai, Yu Shen, Takahiro Kogawa, Diane D. Liu, Angela N. Marx, Naoto T. Ueno, Jennifer K. Litton, Nuhad K. Ibrahim, Bora Lim
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of bre